Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 8, 2017, Pages 1156-1161

  Londono M C ^a   Lens, S ^a   Marino Z ^a   Bonacci, M ^a   Ariza, X ^a   Broquetas, T ^b   Pla, A ^a   Bartres, C ^a   Adriani, M V ^a   Rodriguez Tajes S ^a   Costa, J ^c   Carrion J A ^b   Perez del Pulgar S ^a   Forns, X ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; VIRUS DNA; HEPATITIS B ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PATIENT MONITORING; PROSPECTIVE STUDY; VIRUS REACTIVATION; BLOOD; COMPLICATION; DRUG EFFECTS; HEPATITIS B; HEPATITIS C, CHRONIC; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS ACTIVATION; YOUNG ADULT;

EID: 85013287851     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13985     Document Type: Article

References (24)

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5 Suppl): S156–65.
2. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016; 78: 27–30.
3. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015; 61: 1304–6.
4. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015; 9: 164.
5. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2015; 46: 489–91.
6. Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2016; pii: S1542–3565(16)30370-6. doi: 10.1016/j.cgh.2016.06.023 [Epub ahead of print].
7. Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 2016; 63: 1202–4.
8. Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV. Antivir Ther 2016; 21: 605–9.
9. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–85.
10. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol 2015; 28: 221–8.
11. Nguyen LH, Nguyen MH. Systematic review: asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 37: 921–36.
12. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C–natural history and cofactors. Aliment Pharmacol Ther 2005; 22(Suppl 2): 74–8.
13. Yeh ML, Hung CH, Huang JF, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS ONE 2011; 6: e20752.
14. Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012; 9: 186.
15. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15: 434–41.
16. Maylin S, Sire JM, Mbaye PS, et al. Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B. BMC Infect Dis 2015; 25: 154.
17. Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149: 190–200 e2.
18. Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+T cell function by interferon-free therapy. J Hepatol 2014; 61: 538–43.
19. Perello CS, Fernandez-Carrillo C, Londono MC, et al. Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2016; 14: 1662–6.
20. Tsang CS, Samaranayake LP. Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis 2010; 16: 248–56.
21. Lepelletier C, Salmona M, Bercot B, Maylin S, Sellier PO. First description of past hepatitis B virus infection acute reactivation occurring in a human immunodeficiency virus infected patient as manifestation of immune reconstitution inflammatory syndrome. J Infect Chemother 2016; 22: 490–4.
22. Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016;. doi:10.1016/j.jhep.2016.04.008
23. Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 2016;. doi:10.1016/j.jhep.2016.05.045
24. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727–33.